Entresto Pill
Phase 3Small molecule
Entresto Pill is one of 45 small molecule programs targeting Function. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
55 competitors in Function
#DrugCompanyPhaseTrials
1Indocin
CCosette Pharmaceuticals, Inc.
Approved
Flomax
SanofiPhase 3
Taxol
TevaPhase 2
N-Acetyl Cyteien
SStanford University
Phase 3
Ezallor Sprinkle
AstraZenecaPhase 2
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 2
Paraplatin
AAvyxa
Phase 2
Tuoyi
CCoherus Oncology, Inc.
Phase 2
Xeljanz
PPrism Pharmaceuticals
Phase 2
Golytely
BayerPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Entresto Pill. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- MMayo Clinic